Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s449, 2024. DOI: 10.25251/skin.8.supp.449. Disponível em: https://skin.dermsquared.com/skin/article/view/3053. Acesso em: 17 apr. 2026.